Dong-A and Green Cross to see sustained growth next year

Despite the government’s pressure to cut drug prices and fierce competition, Dong-A Pharmaceutical and Green Cross Corp. will see their revenue and operating profit surge next year, according to a report released by IBK Investment Securities.

The report indicated that the sales of Dong-A will come to 985.7 billion won next year, up 5.1 percent the previous year and its operating profit will ...